[Cited FineTest ELISA Kit] Current Research on Metastatic Colorectal Cancer Treatments

FineTest ELISA kit contributes to the research on colorectal cancer. The immunoassay is designed to measure FGL1 concentration in plasma.

Publication Details
Article Title: The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer
Journal Title: Nature Communications
DOI: 10.1038/s41467-023-42332-0
IF: 16.6
PMID: 37872170

Abstract:    Colorectal cancer (CRC) patients with liver metastases usually obtain less benefit from immunotherapy, and the underlying mechanisms remain understudied. Here, we identify that fibrinogen-like protein 1 (FGL1), secreted from cancer cells and hepatocytes, facilitates the progression of CRC in an intraportal injection model by reducing the infiltration of T cells. Mechanistically, tumor-associated macrophages (TAMs) activate NF-ĸB by secreting TNFα/IL-1β in the liver microenvironment and transcriptionally upregulate OTU deubiquitinase 1 (OTUD1) expression, which enhances FGL1 stability via deubiquitination. Disrupting the TAM-OTUD1-FGL1 axis inhibits metastatic tumor progression and synergizes with immune checkpoint blockade (ICB) therapy. Clinically, high plasma FGL1 levels predict poor outcomes and reduced ICB therapy benefits. Benzethonium chloride, an FDA-approved antiseptics, curbs FGL1 secretion, thereby inhibiting liver metastatic tumor growth. Overall, this study uncovers the critical roles and posttranslational regulatory mechanism of FGL1 in promoting metastatic tumor progression, highlighting the TAM-OTUD1-FGL1 axis as a potential target for cancer immunotherapy.

Keywords:  Colorectal Cancer, Colonic Neoplasms, Liver Neoplasms, Rectal Neoplasms, Tumor Microenvironment, Cancer Immunotherapy

Immunoassay

Validated Image

Figure Source:  Nat Commun. 2023 Oct 23;14(1):6690. doi: 10.1038/s41467-023-42332-0.